clinical trial · NCT06295679
A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease
Amgen·—·recruiting·n = 7,000
Major Cardiovascular EventEstablished Atherosclerotic Cardiovascular Disease
brief summary
The primary objective of the study is to evaluate real-world effectiveness of treatment with Repatha® in combination with SOC, compared with SOC alone, on the risk for cardiovascular (CV) death, myocardial infarction (MI), stroke, hospitalization for unstable angina, or coronary revascularization, whichever occurs first, in participants with established atherosclerotic CV disease (ASCVD) treated with SOC, according to local clinical practice.
started
Dec 19, 2022
primary completion
Dec 19, 2028
completion
Dec 19, 2028
last updated
Feb 20, 2026
official title
A Real-world, Prospective, Observational Study Assessing the Effectiveness of Repatha® Used in Combination With Standard of Care Compared With Standard of Care Alone on Major Cardiovascular Events in Chinese Patients With Established Atherosclerotic Cardiovascular Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol